Venture-backed startup developing first-in-class predictive biomarkers to harness low-toxicity, FDA-approved, repurposed antifibrotic drugs for cancer metastasis prevention. MeCo Diagnostics traces its origins to the oldest observation in cancer biology: tumors often grow stiffer than surrounding tissue, leading to a palpable lump, which is the most common indicator of disease. Not all cancer cells are responsive to increased stiffness of their microenvironment, but those that are become “mechanically conditioned,” akin to deadly, microscopic wind-up machines that are destined to wreak havoc as they spread throughout the body. Mechanical conditioning as a problem dictates mechanical deconditioning as a solution; fortunately, there are FDA-approved antifibrotic drugs which can be repurposed for this need. This serendipity has empowered us to develop a commercially viable, biomarker-enabled drug repurposing approach that synergizes with conventional neoadjuvant treatments. Ultimately, we aim to reduce breast and prostate cancer burden in patients before surgery, leading to higher rates of lifelong remission. Since we are leveraging generic-emergent drugs, the cost of targeted antifibrotic therapy will soon be >10X cheaper than any other targeted therapy for breast or prostate cancer in development. This opportunity is unprecedented.